Startups
EndLyz Therapeutics
EndLyz Therapeutics develops small-molecule modulators of ATP13A2 and ATP10B lysosomal transporters for Parkinson's disease and other neurodegenerative disorders. Founded in2021 by SV Health Investors' Dementia Discovery Fund, the company aims to restore endo-lysosomal function; its initial development focus includes genetic Parkinson's subsets. Its March31,2025 launch announced an exclusive collaboration with KU Leuven researcher and scientific co-founder Peter Vangheluwe, with Quantum AI supporting drug-discovery research. Research goals and planned IND-enabling studies are not claims of clinical efficacy or regulatory approval. The current public directory names six scientific/operating leaders and five board affiliations across ten unique people, led by CEO and co-founder Joanna Wolak. US SEC filings identify Endlyz Therapeutics Inc., Delaware, CIK1875514. The July2021 filing reported USD3.25M equity sold toward a USD6.5M offering; this is an interim snapshot, not proof of final capital. The May2026 filing for a distinct March2026 offering reports USD17,250,395 sold, explicitly including conversions of earlier securities, so new cash cannot be equated to that total. The issuer describes Seed2 financing in2026 without a separately verified cash amount here. March2025 issuer disclosures identify USD2.2M MichaelJFoxFoundation programme funding; paid-to-date and instrument details remain unverified. Published backers include DDF, OxfordScienceEnterprises, AbbVieVentures, Parkinson'sUK and KU Leuven CD3; publication alone does not allocate them to a specific priced event. Current employee completeness and all private investor allocations remain unverified.
Founded 2021
Team
 Craig FoxBoard Member; Oxford Science Enterprises Representative |
 Donmienne LeungBoard Member; AbbVie Ventures Representative |
 Floriana LicitraDirector, Research Biology |
 Joanna WolakCEO and Co-Founder · Board Member |
 John DavisScientific Co-Founder |
 Laurence BarkerBoard Member; SV Health Investors Representative |
 Oscar BarbaHead of Discovery |
 Peter VangheluweScientific Co-Founder |
 Richard Wade-MartinsScientific Co-Founder |
 Tim EdwardsIndependent Chairperson |